Core Viewpoint - The article discusses the implementation of a special HPV vaccine policy in Shenyang's Tiexi District, aimed at promoting public health and preventing HPV-related diseases among both males and females, reflecting a shift towards a more inclusive approach to HPV prevention [1][2]. Group 1: HPV Vaccine Policy - The policy covers females aged 9-45 and males aged 9-26, establishing a comprehensive HPV prevention network that includes targeted protection for youth and ongoing coverage for adult women [1] - Eligible individuals can receive free doses of the HPV vaccine: for the imported quadrivalent vaccine, females aged 9-13 receive the second dose for free, while females aged 14-26, 35-45, and males aged 9-26 receive the third dose for free [1] - The imported nine-valent HPV vaccine offers similar benefits, with free second doses for females aged 9-14 and free third doses for females aged 15-26, 35-45, and males aged 16-26 [1] Group 2: Public Health Impact - The initiative aims to block the HPV transmission chain and reduce the risk of related diseases such as anal and penile cancers in males, marking a transition from a single-gender cervical cancer prevention strategy to a more comprehensive approach [2] - The nine-valent HPV vaccine is the first and only approved vaccine in China that can prevent cancers and diseases caused by persistent HPV infections in both males and females [2] Group 3: Participation and Timeline - The program is open to all eligible individuals regardless of residency, encouraging widespread participation in the health initiative [2] - The vaccination campaign has a time window, with the first dose discount available until November 30, 2025, and individuals must complete their vaccination by May 31, 2026, to benefit from the discounts [2]

Core Viewpoint - The launch of the nine-valent HPV vaccine for male indications in Zibo marks a significant step in promoting HPV vaccination and enhancing public health awareness in China [1][3]. Group 1: HPV Vaccine Approval and Significance - On April 14, the nine-valent HPV vaccine received approval from the National Medical Products Administration for multiple new indications, becoming the first and only HPV vaccine in China approved for both males and females [3]. - The approval signifies China's entry into a new phase of "joint prevention of HPV-related cancers and diseases" for both genders [3]. Group 2: Health Risks and Awareness - HPV infections often show no early symptoms, and the lack of routine screening methods for males makes the disease more insidious, highlighting the importance of increasing male awareness and encouraging vaccination [3][5]. - Males are at risk of HPV infections, with global infection rates actually higher than those of females, making vaccination crucial for preventing anal cancer and genital warts, as well as reducing transmission risks to female partners [5]. Group 3: Target Population and Vaccination Process - The nine-valent HPV vaccine is approved for males aged 16 to 26, requiring a three-dose immunization schedule to prevent various HPV-related diseases [5]. - The vaccine can prevent anal cancer caused by HPV types 16 and 18, genital warts caused by HPV types 6 and 11, and precancerous lesions associated with multiple HPV types [5]. Group 4: Community Engagement and Accessibility - Zibo has opened channels for male residents to book appointments for both four-valent and nine-valent HPV vaccinations through various online platforms, facilitating early vaccination and protection [6]. - The adult vaccination clinic at Shandong University of Technology has quickly responded to the demand for HPV vaccinations among students and staff, emphasizing the role of educational institutions in health promotion [5][6].